DeepMed Research

Cancer Hospital, Chinese Academy of Medical Sciences

🇨🇳China

Country: 🇨🇳China

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Oral Iohexol in the Management of Chylous Ascites After After Retroperitoneal or Extended Lymphadenectomy

Phase 2

Not yet recruiting

Conditions: Retroperitoneal Lymph Node Metastasis
Extended Lymphadenectomy
Chylous Ascites
Abdominal Neoplasm
Pelvic Neoplasms
Retroperitoneal Lymphadenectomy

Interventions: Drug: oral iohexol
Procedure: Lymphangiography and Embolization

First Posted Date: 2025-02-11

Last Posted Date: 2025-02-11

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 30

Registration Number: NCT06820320

Locations: 🇨🇳
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China

Adebrelimab Combined With Nab-paclitaxel, Oxaliplatin and Tegafur (AOS) for Perioperative Treatment of Locally Advanced Resectable GC/GEJ

Phase 2

Recruiting

Conditions: Gastric Adenocarcinoma
Gastro-esophageal Junction Adenocarcinoma

Interventions: Drug: Adebrelimab, Nab-paclitaxel, Oxaliplatin, Tegafur Gimeracil Oteracil Potassium Capsule

First Posted Date: 2025-02-05

Last Posted Date: 2025-02-05

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 61

Registration Number: NCT06808971

Locations: 🇨🇳
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, China

Cadonilimab in Patients (Pts) with Advanced Non-small Cell Lung Cancer (NSCLC)

Phase 2

Recruiting

Conditions: Stage IVB Lung Cancer
Non-Squamous

Interventions: Drug: cadonilimab，bevacizumab，docetaxel

First Posted Date: 2025-01-27

Last Posted Date: 2025-01-27

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 44

Registration Number: NCT06793813

Locations: 🇨🇳
Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China

A Study Comparing the Differences Between Young and Non-young Breast Cancer

Conditions: Breast Cancer

First Posted Date: 2025-01-27

Last Posted Date: 2025-02-14

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 3000

Registration Number: NCT06793306

Locations: 🇨🇳
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China

A Multicenter Prospective Cohort Study of Adjuvant Therapy for BRCA1/2 Mutated Hormone Receptor-positive HER2-negative Early High-risk Breast Cancer

Conditions: Breast

Interventions: Drug: Endocrine drug +CDK4/6 inhibitor or PRAP inhibitor or Endocrine drug +CDK4/6 inhibitor+PARP inhibitor

First Posted Date: 2025-01-24

Last Posted Date: 2025-02-14

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 300

Registration Number: NCT06791161

Locations: 🇨🇳
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China

Albumin-Bound Paclitaxel and Gemcitabine With or Without S-1 as First-Line Treatment for Advanced Pancreatic Cancer

Phase 2

Recruiting

Conditions: Pancreatic Adenocarcinoma

Interventions: Drug: Gemcitabine, albumin-bound paclitaxel
Drug: Gemcitabine, albumin-bound paclitaxel, S-1

First Posted Date: 2025-01-23

Last Posted Date: 2025-01-30

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 128

Registration Number: NCT06789679

Locations: 🇨🇳
National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Chaoyang District, China

A Prospective, Multicenter, Observational Cohort Study Assessing the Efficacy and Safety of Radiotherapy-sensitized Immunotherapy in Advanced Breast Cancer

Recruiting

Conditions: Advanced Breast Cancer

First Posted Date: 2025-01-15

Last Posted Date: 2025-01-15

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 150

Registration Number: NCT06776861

Locations: 🇨🇳
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China

Nimotuzumab High-risk, Locally Advanced Squamous Cell Carcinoma of the Cervix

Phase 2

Active, not recruiting

Conditions: Uterine Cervical Neoplasms

Interventions: Drug: Nimotuzumab Injection

First Posted Date: 2025-01-13

Last Posted Date: 2025-01-13

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 43

Registration Number: NCT06771596

Locations: 🇨🇳
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China

Phase II Clinical Trial of PD-L1 in Combination with Vinorelbine + Cyclophosphamide + Capecitabine (VEX) Metronomic Chemotherapy with or Without Radiotherapy for Advanced Triple-negative Breast Cancer.

Phase 2

Recruiting

Conditions: Advanced Triple-negative Breast Cancer

Interventions: Drug: Adebry single antibody + VEX metronomic chemotherapy + radiotherapy
Drug: debry single antibody + VEX metronomic chemotherapy

First Posted Date: 2025-01-13

Last Posted Date: 2025-01-13

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 150

Registration Number: NCT06771609

Locations: 🇨🇳
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China

Hypofractionated Radiotherapy for HNSCC in Elderly Patients

Not Applicable

Conditions: Head and Neck Cancer Squamous Cell Carcinoma
ELDERLY PEOPLE
Hypofractionation

First Posted Date: 2025-01-10

Last Posted Date: 2025-01-10

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 51

Registration Number: NCT06768125

Locations: 🇨🇳
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy